The Best Anticoagulation Strategy for Cirrhotic Patients who Underwent Splenectomy: A Network Meta-Analysis

Table 2

Summary of findings and evidence qualities for the main comparisons.

Outcomes	Comparison		No. of trails	Hazard ratio (95% CI)	Sample size	Quality of the evidence (GRADE)
Incidence of PVST	Control	versus Antithrombin III	2	0.05 (0.01, 0.24)	103	⊕ ⊕ ⊕
		versus LMWH + Warfarin + Aspirin	1	0.16 (0.10, 0.43)	191	⊕
		versus Urokinase + Aspirin	1	0.10 (0.02, 0.48)	71	⊕ ⊕ ⊕⊕
		versus LMWH + Warfarin	2	0.40 (0.15, 1.08)	164	⊕
	LMWH + Warfarin	Warfarin	1	2.64 (1.59, 4.40)	301	⊕⊕
	Warfarin	Aspirin	2	2.87 (1.43, 5.73)	148	⊕
	Aspirin	LMWH + Aspirin	1	2.31 (1.31, 4.08)	219	⊕
		Alprostadil	1	6.33 (1.27, 31.67)	76	⊕ ⊕ ⊕

GRADE Working Group grades of evidence.
High quality (⊕⊕⊕⊕): further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (⊕⊕⊕): further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality (⊕⊕): further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality (⊕): we are very uncertain about the estimate.